Therapy Areas: Oncology
Champions Oncology expands bioanalytical services with new technology and leadership
8 December 2025 - Champions Oncology Inc (NASDAQ:CSBR), a technology-enabled oncology research organisation, announced on Monday that it has expanded its clinical bioanalytical services with the integ...
Poolbeg Pharma trial to feature in major CRS research programme
8 December 2025 - Biopharmaceutical company Poolbeg Pharma plc (AIM: POLB) announced on Monday that it will participate as lead business partner in a new cancer immunotherapy-induced cytokine release ...
DELFI Diagnostics presents preliminary data showing potential for blood-based lung cancer detection in non-smoking population
8 December 2025 - DELFI Diagnostics Inc, a developer of accessible blood-based, liquid biopsy tests for early cancer detection, on Friday announced the presentation of preliminary data from the Female...
Natera acquires Foresight Diagnostics to expand MRD capabilities
5 December 2025 - Cell-free DNA testing company Natera Inc (NASDAQ:NTRA) announced on Friday that it has acquired Foresight Diagnostics, a leader in ultrasensitive molecular residual disease (MRD) det...
FDA clears Bristol Myers Squibb's Breyanzi as first CAR T therapy for relapsed or refractory marginal zone lymphoma
5 December 2025 - Biopharmaceutical company Bristol Myers Squibb (NYSE:BMY) announced late Thursday that it has received US Food and Drug Administration (FDA) approval for Breyanzi (lisocabtagene mara...
OncoHost named Gold Winner in 2025 Merit Awards for Healthcare
5 December 2025 - OncoHost, a technology company focused on transforming the approach to precision oncology through proteomics and AI, announced on Thursday that it has been honoured as a Gold Winner ...